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frequently in cardiogenic shock patients. Our preliminary data
emphasize the impact on early improvement in hemodynamic pa-
rameters and rapid lowering of lactate levels. Consequent and early
use of a microaxial pump in left-ventricular failure signiﬁcantly con-
tributes to improved survival.
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BACKGROUND High-risk surgical patients for transcatheter aortic
valve replacement (TAVR) represent an emerging population, which
may beneﬁt from short-term use of mechanical support devices
(MSD). We assessed outcomes of TAVRs performed with elective or
emergent “bail-out” placement of MSD.
METHODS All patients undergoing TAVR at a high volume academic
center who required MSD during index procedure between the years
2008-2015 were included.
RESULTS MSD were used in 12.4% (59/475) of all TAVRs (n¼56
Edwards Sapien) of which 70% (n¼41) were used as part of a planned
strategy, and 30% (n¼18) were used in “bail-out” situations. 25% (15/
59) required cardiopulmonary resuscitation and 14% (8/59) required a
second device (Impella or cardiopulmonary bypass, CPB after intra-
aortic balloon pump, IABP). Mean STS was 10 2.66%, 86% had
multivessel coronary artery disease and 69% underwent transapical
TAVR. IABP (81%) was the most commonly used device followed by
CPB and Impella. MSD were placed electively in patients with severe
left ventricular dysfunction undergoing concomitant coronary inter-
vention or balloon valvuloplasty whereas “bail-out” indications were
procedural complications including cardiac arrest (VT/VF) (n¼5), re-
fractory hypotension (n¼5), cardiac tamponade (n¼2), severe aortic
insufﬁciency (n¼2), stone heart or LV failure (n¼2), valve emboliza-
tion (n¼1), and left main obstruction + PCI (n¼1). Mean duration of
support was 1-day and device related complications were low (3%). In-
hospital mortality in this extremely high risk population was 17% (8%
for elective cases and 44% for emergent cases) compared to 5% in
patients without MSD use (control group). Cardiogenic shock (50%)
was the most common cause of in-hospital death followed by respi-
ratory and multi-organ failure. The cumulative all-cause mortality at
one-year follow-up was 71% (90% for elective and 50% for emergent
cases) (Figure 1).CONCLUSIONS Use of MSD in TAVR is associated with a signiﬁcantly
high mortality rates. The dismal long-term survival especially in the
elective MSD group raises concerns about the use of MSD and perhaps
futility of TAVR in this high-risk patient population.
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BACKGROUND The 6-Fr Glidesheath Slender that has a thinner wall
structure and the same outer diameter compared to the conventional
5-Fr introducer has been introduced for trans-radial coronary inter-
vention. The aim of this study was to evaluate the feasibility and
safety of the 6-Fr Glidesheath Slender for use with the 6-Fr intra-
aortic balloon pump (IABP) catheter.
METHODS Between May 2014 and March 2015, 24 patients with acute
coronary syndrome underwent percutaneous coronary intervention
using a 6-Fr IABP catheter with a balloon volume of 30 ml through a 6-
Fr Glidesheath Slender for support. The adverse events, including
access site complications, kinking of the sheath during the procedure,
and any evidence of balloon pump failure, were retrospectively
investigated.
RESULTS Insertion of the IABP catheter through either the femoral or
brachial artery was successful in all patients. The mean support time
was 32.4  22.0 h. No major hemorrhagic event or severe limb
ischemia was observed. Kinking of the shaft occurred during insertion
in one patient; however, the subsequent balloon pumping was well
maintained and did not require exchange of the sheath or IABP
catheter. No kind of IABP failure was observed.Virtual 5-Fr IABPBaseline Patient Characteristics and ResultsAge (years) 68.9  9.8
Male gender (%) 16 (66.7)Height (cm) 159.5  10.5
Body weight (kg) 59.0  10.7
Body surface area (m2) 1.60  0.19
IABP approach site - femoral (%) 24 (95.8)IABP approach site - brachial (%) 3 (12.5)Support time of IABP (hr) 32.4  22.0
Kinking of sheath introducer (%) 1 (4.2)Access site complication (%) 0 (0)CONCLUSIONS Although this sheath was originally designed to allow
radial access, our results suggest that the use of the Glidesheath
Slender is feasible for insertion of the 6-Fr IABP catheter through the
brachial and femoral arteries, and may reduce vascular complications
in patients who undergo percutaneous coronary intervention.
